[3]. Fitzpatrick MC, Laufer RS, Baral R, et al. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022. Vaccine 2023; 41: 7047–59. [4]. Wang X, Li Y, Shi T, et ...
“A Good Day”: FDA Approves World’s First RSV Vaccine. Nature 2023, 617, 234–235. [Google Scholar] [CrossRef] Bouzid, D.; Visseaux, B.; Ferré, V.M.; Peiffer-Smadja, N.; Le Hingrat, Q.; Loubet, P. Respiratory Syncytial Virus in Adults with Comorbidities: An Update on ...
In May 2023, the U.S. FDA advisors endorsed Pfizer’s pregnancy-administered vaccine (branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection. Vaccination can reduce the burden of RSV-related respiratory disease, with previou